Cancer treatments

New Data From the Phase I Study of Birinapant in Combination With Keytruda® Will be Presented at the ASCO 2019

Retrieved on: 
Thursday, May 16, 2019
Health, Life sciences, Medicine, Medivir, Cancer immunotherapy, Oncology, Cancer treatments

Based on its unique design and mechanism, birinapant has the potential to enhance patients' responses in combination with other treatments.

Key Points: 
  • Based on its unique design and mechanism, birinapant has the potential to enhance patients' responses in combination with other treatments.
  • Medivir's initial focus is on developing birinapant in combination with an immuno-oncology agent.
  • Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

Retrieved on: 
Wednesday, May 15, 2019
Cancer treatments, Clinical medicine, Cancer, Antineoplastic drugs, Tyrosine kinase receptors, Breakthrough therapy, AXL receptor tyrosine kinase, Pembrolizumab, Bemcentinib, Non-small-cell lung carcinoma, Chemotherapy, Cancer immunotherapy

Phase II clinical trial assessing bemcentinib in combination with pembrolizumab (KEYTRUDA) in advanced lung cancer patients post chemotherapy.

Key Points: 
  • Phase II clinical trial assessing bemcentinib in combination with pembrolizumab (KEYTRUDA) in advanced lung cancer patients post chemotherapy.
  • Promising clinical activity continues to be seen overall, particularly in patients with AXL positive tumours including those with weak or no PD-L1 expression.
  • First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with low dose AraC (LDAC) or decitabine exerts anti-leukaemia activity in AML pts unfit for intensive chemotherapy: Phase II open-label study.
  • Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "We are encouraged by the promising data that continues to emerge from our clinical development programme with bemcentinib in AML and NSCLC.

BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

Retrieved on: 
Wednesday, May 15, 2019
Cancer treatments, Clinical medicine, Cancer, Antineoplastic drugs, Tyrosine kinase receptors, Breakthrough therapy, AXL receptor tyrosine kinase, Pembrolizumab, Bemcentinib, Non-small-cell lung carcinoma, Chemotherapy, Cancer immunotherapy

Phase II clinical trial assessing bemcentinib in combination with pembrolizumab (KEYTRUDA) in advanced lung cancer patients post chemotherapy.

Key Points: 
  • Phase II clinical trial assessing bemcentinib in combination with pembrolizumab (KEYTRUDA) in advanced lung cancer patients post chemotherapy.
  • Promising clinical activity continues to be seen overall, particularly in patients with AXL positive tumours including those with weak or no PD-L1 expression.
  • First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with low dose AraC (LDAC) or decitabine exerts anti-leukaemia activity in AML pts unfit for intensive chemotherapy: Phase II open-label study.
  • Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "We are encouraged by the promising data that continues to emerge from our clinical development programme with bemcentinib in AML and NSCLC.

Rakuten Medical Highlights Upcoming Presentations and Activities During the ASCO Annual Meeting, May 31 - June 4, 2019 in Chicago

Retrieved on: 
Wednesday, May 15, 2019
Medicine, Cancer treatments, Clinical medicine, Oncology, Antineoplastic drugs, Antibody-drug conjugates, Immunotherapy

In addition, study criteria and details on Rakuten Medical's Phase 3 clinical trial of ASP-1929 PIT therapy versus physician's choice standard-of-care for the treatment of patients with locoregional rHNSCC will also be highlighted during a poster presentation.

Key Points: 
  • In addition, study criteria and details on Rakuten Medical's Phase 3 clinical trial of ASP-1929 PIT therapy versus physician's choice standard-of-care for the treatment of patients with locoregional rHNSCC will also be highlighted during a poster presentation.
  • It is conjugated to a photoactivatable dye (IRDye 700DX).
  • Binding of the antibody-dye conjugate to cancer cells, followed by a photoactivation with non-thermal red light, induces selective and rapid necrosis of cancer cells with minimal damage to surrounding tissue.
  • Patients with rHNSCC have few curative treatment options available and low response rates; therefore, new modalities that can be targeted, minimally invasive, and provide improved tumor response and control with limited side effects are needed.

MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, May 15, 2019
Cancer treatments, Medicine, RTT, Clinical medicine, Follicular lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Lymphoma, Draft:HDAC inhibitors in cancer treatment, Phosphoinositide 3-kinase inhibitor

Study investigators will present updated results from the Phase 1b study evaluating ME-401 in relapsed/refractory follicular lymphoma and complete results from the investigator-initiated study of ME-344 in combination with Avastin in patients with HER2-negative breast cancer.

Key Points: 
  • Study investigators will present updated results from the Phase 1b study evaluating ME-401 in relapsed/refractory follicular lymphoma and complete results from the investigator-initiated study of ME-344 in combination with Avastin in patients with HER2-negative breast cancer.
  • The abstract relates to updated data from the Phase 1b study evaluating ME-401 in relapsed/refractory follicular lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma, both as a monotherapy and in combination with rituximab.
  • In addition, mitochondrial inhibitor ME-344 continues to generate investigator support and interest for its novel MOA and combination potential with Avastin in breast cancer."
  • We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer

Retrieved on: 
Wednesday, May 15, 2019
Cancer treatments, Cancer, Monoclonal antibodies, Drugs, Eli Lilly and Company, Ramucirumab, Epidermal growth factor receptor

Data from 23 oral presentations and posters underscore Lilly Oncology's focus on making a meaningful difference in the lives of people living with cancer, especially those with hard-to-treat tumor types.

Key Points: 
  • Data from 23 oral presentations and posters underscore Lilly Oncology's focus on making a meaningful difference in the lives of people living with cancer, especially those with hard-to-treat tumor types.
  • "Lilly data at this year's ASCO demonstrate our commitment to offering treatment solutions for patients with the greatest need.
  • "We are excited to present the first results from RELAY, a Phase 3 study of ramucirumab in metastatic EGFR-mutated non-small cell lung cancer.
  • Lilly will also share early-phase data from several investigational molecules as well as results from collaborative studies.

ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Medicine, Clinical medicine, Cancer, RTT, Cancer treatments, Genentech, Antineoplastic drugs, Bevacizumab, Ovarian cancer, ImmunoGen, Antibody-drug conjugate

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin (bevacizumab) in patients with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer.

Key Points: 
  • ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin (bevacizumab) in patients with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer.
  • Our goal remains to establish mirvetuximab as the combination agent of choice in ovarian cancer, supporting its use in earlier lines of therapy.
  • These mature data support further exploration of this doublet, as well as the ongoing expansion study evaluating a triplet combination of mirvetuximab with Avastin and carboplatin in patients with platinum-sensitive disease.
  • I look forward to further evaluating mirvetuximab in combination with Avastin as well as in the triplet with carboplatin.

Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Hospitals, Oncology, Pharmaceutical, Medicine, Cancer treatments, Gene therapy, Clinical medicine, Health, Axicabtagene ciloleucel, Breakthrough therapy, Risk Evaluation and Mitigation Strategies, Rems, Kite, Forward-looking statement

Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution.

Key Points: 
  • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution.
  • Yescarta is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta REMS.
  • The median time to onset was 2 days (range: 1-12 days) and median duration was 7 days (range: 2-58 days).
  • All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.

Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Cancer treatments, Clinical medicine, Monoclonal antibodies, Seattle Genetics, Medicine, Takeda Pharmaceutical Company, Antibody-drug conjugates, Immunology, Brentuximab vedotin, CD30, Monomethyl auristatin E

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time.
  • The presentation will be webcast live and available for replay from Seattle Genetics website at www.seattlegenetics.com in the Investors section.
  • Seattle Genetics, Inc.is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives.
  • ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.

Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBio

Retrieved on: 
Wednesday, May 15, 2019
Stem cells, Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Cancer treatments, Medicine, Clinical medicine, Health, Virotherapy, Galena Biopharma, Immunotherapy, Checkpoint inhibitor, Cancer

The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced the appointment of Bijan Nejadnik, M.D., as its new Chief Medical Officer in charge of development and regulatory affairs.

Key Points: 
  • The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced the appointment of Bijan Nejadnik, M.D., as its new Chief Medical Officer in charge of development and regulatory affairs.
  • As Chief Medical Officer at Galena Biopharma, he led the research of immunotherapy for multiple cancers and research in adoptive T-cell therapy in combination with checkpoint inhibitor drugs.
  • As Chief Medical Officer at Eureka Therapeutics, he was involved in the development of genetically modified T-cells and obtained FDA approval for several IND and launched the clinical trials.
  • I am very pleased to welcome Dr. Bijan Nejadnik as SanBios new Chief Medical Officer, said Keita Mori, CEO of SanBio, Co., Ltd.